COMP <GO>
NTRA vs ABBV // FORWARD P/E MULTIPLE
Natera Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NTRA 3
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: NTRA
LAST: $436.00 (+2.73%) • MKT CAP: $62.85B
forward-pe
18.0x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NTRA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NTRA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.90% | 29.00% | -33.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.17% | 3.47% | -3.30 | ABBV | /fcf-yield <GO> |
| Operating Margin | -13.40% | 24.60% | -38.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -9.00% | 6.90% | -15.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 35.90% | 8.60% | +27.30 | NTRA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | NTRA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.0 | 65.1 | -1.10 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 1.15 | -0.06 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 18.0x | 113.1x | -95.10 | NTRA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $62.85B | $513.86B | -$451.01B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NTRA REV | ABBV REV | NTRA GROSS % | ABBV GROSS % | NTRA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.31B | $61.16B | — | 70.2% | $109.1M | $17.82B |
| FY 2024 | $1.70B | $56.33B | — | 70.0% | $69.2M | $17.83B |
| FY 2023 | $1.08B | $54.32B | — | — | -$295.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NTRA // BETA 1.09
ABBV // BETA 1.15